Piperazine → [4-(5-Piperazin-1-yl-thiazol-2-yl)-pyrimidin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine

HRID 1178209

반응식

HRID 1178209 반응식
Cl[C:2]1[S:6][C:5]([C:7]2[CH:12]=[CH:11][N:10]=[C:9]([NH:13][C:14]3[CH:19]=[C:18]([O:20][CH3:21])[C:17]([O:22][CH3:23])=[C:16]([O:24][CH3:25])[CH:15]=3)[N:8]=2)=[N:4][CH:3]=1.[NH:26]1[CH2:31][CH2:30][NH:29][CH2:28][CH2:27]1>CS(C)=O>[N:26]1([C:2]2[S:6][C:5]([C:7]3[CH:12]=[CH:11][N:10]=[C:9]([NH:13][C:14]4[CH:19]=[C:18]([O:20][CH3:21])[C:17]([O:22][CH3:23])=[C:16]([O:24][CH3:25])[CH:15]=4)[N:8]=3)=[N:4][CH:3]=2)[CH2:31][CH2:30][NH:29][CH2:28][CH2:27]1

참가 물질

4

반응물 2

HCID 4837PiperazineHCID 58974673[4-(5-Chloro-thiazol-2-yl)-pyrimidin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine

생성물 1

HCID 58974674[4-(5-Piperazin-1-yl-thiazol-2-yl)-pyrimidin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine수율 25%

시약·촉매·용매 1

HCID 679Dimethyl Sulfoxide용매

반응 조건

온도
100 °C

실험 절차

To solution of [4-(5-Chloro-thiazol-2-yl)-pyrimidin-2-yl]-(3,4,5-trimethoxy-phenyl)-amine (150 mg) in dimethylsulfoxide (2 ml) was added piperazine (300 mg). The mixture was heated to 100° C. for 5 hours then allowed to cool and concentrated under high vacuum to an oil. The residue was purified by HPLC with 0.1% TFA/water acetonitrile as eluant to afford the sub-titled compound as an yellow solid (40 mg, 25%); IR (solid) 1567, 1504, 1432, 1411 cm−1; 1H NMR (400 Mhz, CDCl3) δ 1.3-1.5 (1H, br s), 3.1 (4H, s), 3.25 (4H, s), 3.85 (3H, s), 3.95 (6H, s), 7.05 (1H, s), 7.15 (1H, s), 7.19 (1H, s), 7.40 (1H, m), 8.6 (1H, d); MS (ES+) 429.3 (M+1), (ES−) 427.3 (M−1).

후처리

  1. temperatureto cool
  2. concentrationconcentrated under high vacuum to an oil
  3. customThe residue was purified by HPLC with 0.1% TFA/water acetonitrile as eluant

출처 및 근거

ORD 기록
ord-65f54278019f4e40ba4d907565301998
출처 데이터셋
uspto-grants-2007_10
특허 번호
US07276502B2

연결된 노트

불러오는 중…